More than 10,000 rare diseases affect over 30 million people in the United States alone, and 95 percent of those diseases have no approved treatment. With more than 1,000 active clinical programs working to change that, the pressure on biopharmaceutical manufacturers to accelerate the pipeline without compromising quality or compliance has never been greater.
The post Visibility for BioPharma Operations: From Data Insights to Better Outcomes appeared first on the Emerson Automation Experts blog.